Ignite Creation Date:
2025-12-24 @ 10:34 PM
Ignite Modification Date:
2025-12-25 @ 8:06 PM
Study NCT ID:
NCT03526835
Status:
RECRUITING
Last Update Posted:
2025-01-29
First Post:
2018-04-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015179', 'term': 'Colorectal Neoplasms'}, {'id': 'D013274', 'term': 'Stomach Neoplasms'}, {'id': 'D000077195', 'term': 'Squamous Cell Carcinoma of Head and Neck'}, {'id': 'D004938', 'term': 'Esophageal Neoplasms'}], 'ancestors': [{'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}, {'id': 'D013272', 'term': 'Stomach Diseases'}, {'id': 'D002294', 'term': 'Carcinoma, Squamous Cell'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D004935', 'term': 'Esophageal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C582435', 'term': 'pembrolizumab'}, {'id': 'C410216', 'term': 'Folfox protocol'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 523}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2018-05-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2027-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-01-27', 'studyFirstSubmitDate': '2018-04-04', 'studyFirstSubmitQcDate': '2018-05-15', 'lastUpdatePostDateStruct': {'date': '2025-01-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-05-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-11', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Escalation: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1', 'timeFrame': '4 weeks', 'description': 'Evaluation of the number and severity of participants with treatment related toxicities observed during the dose escalation.'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer, and combination cohorts): Safety and tolerability: AEs and SAEs', 'timeFrame': '6-12 months', 'description': 'Incidence, severity, and relationship of AEs and SAEs'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Treatment discontinuations and dose modifications due to AEs', 'timeFrame': '6-12 months', 'description': 'Treatment discontinuations due to AEs and dose modifications due to AEs'}, {'measure': 'Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): Best overall response (BOR)', 'timeFrame': '36 months', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining Best overall response (BOR)'}, {'measure': 'Expansion (Single agent - non-randomized, and combination cohorts): Objective response rate (ORR)', 'timeFrame': '36 months', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining objective response rate (ORR)'}, {'measure': 'Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEs', 'timeFrame': '8 weeks', 'description': 'Incidence of TEAEs at Week 8'}], 'secondaryOutcomes': [{'measure': 'Escalation & Expansion: Duration of response (DOR)', 'timeFrame': '36 months', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining duration of response (DOR)'}, {'measure': 'Expansion: Progression Free Survival (PFS)', 'timeFrame': '36 months', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining progression free survival (PFS)'}, {'measure': 'Expansion (mCRC combination cohorts): Progression Free Survival (PFS) rate at 4 months', 'timeFrame': '4 months', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining progression free survival (PFS) rate at 4 months'}, {'measure': 'Expansion (Single agent - non-randomized cohorts): Overall survival (OS)', 'timeFrame': '36 months', 'description': 'Evaluation of clinical benefit determining overall survival (OS)'}, {'measure': 'Escalation & Expansion (single agent - non-randomized cohorts): Safety and tolerability: AEs and SAEs', 'timeFrame': 'up to 30 days post-last dose', 'description': 'Incidence, severity, and relationship of AEs and SAEs'}, {'measure': 'Escalation & Expansion (Single agent - non-randomized and Combination cohorts): Treatment discontinuations and dose modifications due to AEs', 'timeFrame': 'up to 30 days post-last dose', 'description': 'Treatment discontinuations due to AEs and dose modifications due to AEs'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: Target Lesions', 'timeFrame': '8 weeks', 'description': 'Percentage change from baseline in sum of the diameters of target lesions at Week 8'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: Grade 3-4 TEAEs', 'timeFrame': '8 weeks', 'description': 'Incidence of Grade 3-4 TEAEs at Week 8'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: IRR TEAEs', 'timeFrame': '8 weeks', 'description': 'Incidence of IRR TEAEs at Week 8'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg : non-IRR TEAEs', 'timeFrame': '8 weeks', 'description': 'Incidence of non-IRR TEAEs at Week 8'}, {'measure': 'Escalation and Expansion: Safety and tolerability: laboratory values', 'timeFrame': '6-12 months', 'description': 'Number of participants with abnormal laboratory tests results'}, {'measure': 'Escalation and Expansion: Safety and tolerability: (ECG)', 'timeFrame': '6-12 months', 'description': 'Number of participants with abnormal ECG readings'}, {'measure': 'Escalation and Expansion: Safety and tolerability: vital signs', 'timeFrame': '6-12 months', 'description': 'Number of participants with abnormal vital signs'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Objective response rate (ORR)', 'timeFrame': '36 months', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining objective response rate (ORR)'}, {'measure': 'Escalation & Expansion: Incidence of anti-drug antibodies against MCLA-158', 'timeFrame': '36 months', 'description': 'Number of participants with anti-drug antibodies against MCLA-158'}, {'measure': 'Escalation: Cytokine Panel Expression Profile', 'timeFrame': '36 months', 'description': 'Evaluation of the cytokine expression profile'}, {'measure': 'Escalation & Expansion: End of infusion (EOI) plasma concentration [Ceoi]', 'timeFrame': '36 months', 'description': 'End of infusion (EOI) plasma concentration \\[Ceoi\\] as measured from all individual plasma concentrations'}, {'measure': 'Escalation & Expansion: Maximum plasma concentration [Cmax]', 'timeFrame': '36 months', 'description': 'Maximum plasma concentration as measured from all individual plasma concentrations'}, {'measure': 'Escalation & Expansion: Plasma concentration at 0 hours [C0h]', 'timeFrame': '36 months', 'description': 'Plasma concentration at 0 hours \\[C0h\\] as measured from all individual plasma concentrations'}, {'measure': 'Escalation & Expansion: Area under the concentration versus time curve from time zero to time t [AUC0-t]', 'timeFrame': '36 months', 'description': 'Area under the concentration versus time curve from time zero to time t \\[AUC0-t\\]'}, {'measure': 'Escalation & Expansion: Area under the concentration versus time curve [AUC0-∞]', 'timeFrame': '36 months', 'description': 'Area under the concentration versus time curve \\[AUC0-∞\\]'}, {'measure': 'Escalation & Expansion: Clearance of plasma [CL]', 'timeFrame': '36 months', 'description': 'Clearance of plasma \\[CL\\]'}, {'measure': 'Escalation & Expansion: Volume of distribution at steady state [Vss]', 'timeFrame': '36 months', 'description': 'Volume of distribution at steady state \\[Vss\\]'}, {'measure': 'Escalation & Expansion: Half-life [t1/2]', 'timeFrame': '36 months', 'description': 'Half-life \\[t1/2\\]'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Bispecific antibody', 'First-in-human', 'MCLA-158', 'Antibodies', 'Bispecific', 'immunologic factors', 'Cytokines', 'EGFR', 'LGR5'], 'conditions': ['Advanced/Metastatic Solid Tumors', 'Colorectal Cancer', 'Gastric Cancer', 'Gastroesophageal-junction Cancer', 'NSCLC', 'HNSCC', 'Head and Neck Squamous Cell Carcinoma', 'Esophageal Cancer']}, 'descriptionModule': {'briefSummary': 'This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.\n\nThe dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC).\n\nThe study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.', 'detailedDescription': 'Study Design:\n\nThis open label, multicenter, first-in-human study consists of 2 parts. Part 1 is a dose escalation to find the recommended Phase II dose (RP2D) of MCLA-158 studying patients with metastatic colorectal cancer (mCRC). Enrollment in the dose escalation part has been completed.\n\nIn the dose expansion (single-agent cohorts) part of the study, the activity, safety, and tolerability of MCLA-158 at 1500 mg every 2 weeks (Q2W) (preliminary RP2D) as a single agent will be evaluated in cohorts of selected solid tumor indications with dependency on EGFR signaling. The most recently enrolled cohorts were in patients with head and neck squamous cell carcinoma (HNSCC). Enrollment into the HNSCC cohort of single-agent MCLA-158 for the treatment of patients with second/third line (2L/3L) HNSCC is closed. In the dose expansion part of the study, safety was also characterized at two dose levels in this setting. Other closed cohort indications included gastric/gastroesophageal junction adenocarcinoma (GEA) with EGFR amplification and/or high EGFR expression, esophageal carcinoma, and pancreatic adenocarcinoma. Enrollment is currently being explored in mCRC (RAS/RAF wild type) patients in the 3L/4L/5L setting.\n\nAdditionally, in the dose expansion (combination cohorts) part of the study, the activity, safety, and tolerability of MCLA-158 at 1500 mg Q2W will be evaluated in combination with other therapies. Enrollment in the combination cohort of treatment of MCLA-158 with pembrolizumab for the treatment of patients with first line (1L) HNSCC is closed. Additionally, two combination cohorts of MCLA-158 with FOLFIRI or with FOLFOX chemotherapy (i.e., 5-fluorouracil \\[5-FU\\], leucovorin, and irinotecan (FOLFIRI) or oxaliplatin (FOLFOX)) will be explored in mCRC (RAS/RAF wild type) patients in the 1L/2L setting. Other expansion cohorts may be considered for monotherapy or combination treatment in the future.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Histologically or cytologically confirmed solid tumors with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.\n* A baseline fresh tumor sample (FFPE) from a metastatic or primary site (if safe/feasible).\n* Amenable for biopsy (if safe/feasible).\n* Measurable disease as defined by RECIST version 1.1 by radiologic methods.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy ≥ 12 weeks, as per investigator.\n* Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA).\n* Adequate organ function\n* Expansion cohorts: patients with locally advanced unresectable or metastatic disease for the following indications:\n\nSINGLE AGENT:\n\n* SECOND-/THIRD-LINE HNSCC PATIENTS (cohort closed to enrolment): patients who have progressed on or after, or are intolerant to, anti-PD-(L)1 therapy and platinum therapy as monotherapy or in combination with other agents and no previous exposure to EGFR inhibitors. Patients treated with platinum-containing therapy only in the adjuvant setting, or in the context of multimodal therapy for locally advanced disease should have disease progression within 6 months of the last dose of platinum containing therapy. Patients with no more than 2 prior lines of treatment in recurrent or metastatic disease.\n\n * Human papilloma virus (HPV) status determined by p16 immunohistochemistry (IHC) or molecular HPV test for all oropharyngeal tumors should be reported when available.\n * The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.\n* 3L+ mCRC (cohort open to enrolment) patients must have:\n\n * No oncogenic missense mutations in KRAS, NRAS, BRAF, or EGFR ectodomain, and no HER2 (ERBB2) amplification, as detected in plasma by ctDNA NGS central testing performed during screening.\n * A microsatellite stable (MSS) tumor.\n\nCOMBINATION:\n\n* FIRST-LINE HNSCC (cohort closed to enrolment): patients eligible to receive pembrolizumab as first-line monotherapy with tumors expressing programmed cell death protein ligand 1 (PD-L1), combined positive score (CPS) ≥1, as determined by a Food and Drug Administration (FDA) approved test in the US, or by an approved equivalent test in other countries; patients should not have previous systemic therapy administered in the recurrent or metastatic setting, although previous systemic therapy as part of multimodal treatment for locally advanced disease is allowed if ended ≥6 months prior to signing the ICF. The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx. Previous treatments with anti PD-(L)1 or anti-EGFR therapies are not allowed.\n* mCRC (cohorts open to enrolment): Patients should have been previously diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. Patients must be RAS/RAF WT as determined using tumor tissue (primary or metastatic) by an appropriate tumor tissue based assay, to be confirmed by the sponsor, and must have an MSS tumor. Patients must be naive to prior anti-EGFR therapy.\n\n * Cohort to be treated with petosemtamab and FOLFIRI: patients may have received up to 1 prior chemotherapy regimen for the metastatic setting, consisting of 1L fluoropyrimidine-oxaliplatin-based chemotherapy ± bevacizumab.\n * Cohort to be treated with petosemtamab and FOLFOX: patients may have received up to 1 prior chemotherapy regimen in the metastatic setting consisting of 1L fluoropyrimidine-irinotecan-based chemotherapy ± bevacizumab.\n\nExclusion Criteria:\n\n* Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.\n* Known leptomeningeal involvement.\n* Participation in another clinical study or treatment with any investigational drug within 4 weeks prior to study entry.\n* Any systemic anticancer therapy within 4 weeks or 5 half-lives whichever is shorter of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity ( e.g. mitomycin C,nitrosoureas), or anticancer immunotherapies, a washout period of 6 weeks is required.\n* Requirement for immunosuppressive medication (e.g. methotrexate, cyclophosphamide)\n* Major surgery or radiotherapy within 3 weeks of the first dose of study treatment. Patients who received prior radiotherapy to ≥25% of bone marrow are not eligible, irrespective of when it was received.\n* Persistent grade \\>1 clinically significant toxicities related to prior antineoplastic therapies (except for alopecia); stable sensory neuropathy ≤ grade 2 NCI-CTCAE v4.03 is allowed.\n* History of hypersensitivity reaction to any of the excipients of petosemtamab, human proteins or any non-IMP treatment required for this study.\n* Uncontrolled hypertension (systolic blood pressure \\[BP\\] \\> 150 mmHg and/or diastolic BP \\> 100 mmHg) with appropriate treatment or unstable angina.\n* History of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia).\n* History of myocardial infarction within 6 months of study entry.\n* History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease for 3 years.\n* Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy.\n* Patients with a history of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of ILD on baseline chest computerized tomography (CT) scan.\n* Current serious illness or medical conditions including, but not limited to uncontrolled active infection,clinically significant pulmonary, metabolic or psychiatric disorders.\n* Patients with known infectious diseases:\n\n * Active hepatitis B infection ((hepatitis B surface antigen \\[HBsAg\\] positive) without receiving antiviral treatment.\n * Positive test for hepatitis C ribonucleic acid (HCV) RNA).\n* Pregnant or breastfeeding patients; patients of childbearing potential must use highly effective contraception methods prior to study entry, for the duration of study participation, and for 6 months after the last dose of MCLA-158.'}, 'identificationModule': {'nctId': 'NCT03526835', 'briefTitle': 'A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors', 'organization': {'class': 'INDUSTRY', 'fullName': 'Merus N.V.'}, 'officialTitle': 'Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors', 'orgStudyIdInfo': {'id': 'MCLA-158-CL01'}, 'secondaryIdInfos': [{'id': '2017-004745-24', 'type': 'EUDRACT_NUMBER'}, {'id': '2024-513627-16-01', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'MCLA-158', 'description': 'In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment.\n\nIn Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days. In addition, in the expansion phase, one randomized cohort will evaluate 2 doses (1100 mg and 1500 mg) of MCLA-158 in head and neck squamous cell carcinoma patients.', 'interventionNames': ['Drug: MCLA-158']}, {'type': 'EXPERIMENTAL', 'label': 'MCLA-158 + Pembrolizumab', 'description': 'MCLA-158 in combination with pembrolizumab will be explored first in head and neck squamous cell carcinoma patients eligible to receive pembrolizumab as first-line monotherapy.', 'interventionNames': ['Combination Product: MCLA-158 + Pembrolizumab']}, {'type': 'EXPERIMENTAL', 'label': 'MCLA-158 + FOLFIRI combination chemotherapy', 'description': 'MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.', 'interventionNames': ['Combination Product: MCLA-158 + FOLFIRI']}, {'type': 'EXPERIMENTAL', 'label': 'MCLA-158 + FOLFOX combination chemotherapy', 'description': 'MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.', 'interventionNames': ['Combination Product: MCLA-158 + FOLFOX']}], 'interventions': [{'name': 'MCLA-158', 'type': 'DRUG', 'otherNames': ['petosemtamab'], 'description': 'full-length IgG1 bispecific antibody targeting EGFR and LGR5', 'armGroupLabels': ['MCLA-158']}, {'name': 'MCLA-158 + Pembrolizumab', 'type': 'COMBINATION_PRODUCT', 'otherNames': ['petosemtamab'], 'description': 'MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.', 'armGroupLabels': ['MCLA-158 + Pembrolizumab']}, {'name': 'MCLA-158 + FOLFIRI', 'type': 'COMBINATION_PRODUCT', 'otherNames': ['petosemtamab'], 'description': 'MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.', 'armGroupLabels': ['MCLA-158 + FOLFIRI combination chemotherapy']}, {'name': 'MCLA-158 + FOLFOX', 'type': 'COMBINATION_PRODUCT', 'otherNames': ['petosemtamab'], 'description': 'MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.', 'armGroupLabels': ['MCLA-158 + FOLFOX combination chemotherapy']}]}, 'contactsLocationsModule': {'locations': [{'zip': '92093', 'city': 'La Jolla', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Petrea Monson', 'role': 'CONTACT', 'phone': '858-246-5674'}], 'facility': 'UCSD', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '90033', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sandy Tran', 'role': 'CONTACT', 'phone': '323-865-3935'}], 'facility': 'USC Norris Comprehensive Cancer Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Danica Griffin', 'role': 'CONTACT'}], 'facility': 'Sharp Healthcare', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '80124', 'city': 'Lone Tree', 'state': 'Colorado', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Jennifer Hege', 'role': 'CONTACT'}], 'facility': 'Rocky Mountain Cancer Centers', 'geoPoint': {'lat': 39.55171, 'lon': -104.8863}}, {'zip': '33901', 'city': 'Fort Myers', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Sufficient Bien', 'role': 'CONTACT', 'phone': '941-907-4737'}], 'facility': 'Florida Cancer Specialists', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'zip': '32827', 'city': 'Orlando', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Ingrid Acker', 'role': 'CONTACT', 'phone': '689-216-8500'}], 'facility': 'Sarah Cannon Research Institute (Lake Nona)', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Rowan Cutler', 'role': 'CONTACT'}], 'facility': 'Massachusetts General Hospital - Dana Farber', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Cynthia Cantrell', 'role': 'CONTACT', 'email': 'cynthia.cantrell@health.slu.edu'}], 'facility': 'SSM Health Saint Louis University Hospital', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Olive Pressey', 'role': 'CONTACT'}], 'facility': 'Washington University School of Medicine at St Louis', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '14850', 'city': 'Ithaca', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Danielle Rao', 'role': 'CONTACT'}], 'facility': 'Cayuga Medical Center', 'geoPoint': {'lat': 42.44063, 'lon': -76.49661}}, {'zip': '13057', 'city': 'Syracuse', 'state': 'New York', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kimberly Desimone', 'role': 'CONTACT'}], 'facility': 'Hematology-Oncology Associates of Central New York', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Anil Timur', 'role': 'CONTACT', 'email': 'timura@ccf.org'}], 'facility': 'Cleveland Clinic', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '43537', 'city': 'Maumee', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Stephanie Ambrose', 'role': 'CONTACT'}], 'facility': 'Taylor Cancer Research Center', 'geoPoint': {'lat': 41.56283, 'lon': -83.65382}}, {'zip': '73102', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Caitlin Merrick', 'role': 'CONTACT', 'phone': '405-464-7300'}], 'facility': 'SSM OKC Hightower Clinical', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '38103', 'city': 'Memphis', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Thomas Kerby', 'role': 'CONTACT', 'email': 'tkerby@uthsc.edu'}], 'facility': 'The University Of Tennessee Health Science Center', 'geoPoint': {'lat': 35.14953, 'lon': -90.04898}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Sarah Cannon Research Institute', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '75246', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Collin Basham', 'role': 'CONTACT', 'email': 'Collin.basham@usoncology.com'}], 'facility': 'Texas Oncology', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Carlos Cortez', 'role': 'CONTACT', 'phone': '713-600-0978'}], 'facility': 'Oncology Consultants', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '75702', 'city': 'Tyler', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kim Chadwick', 'role': 'CONTACT', 'email': 'kim.chadwick@usoncology.com'}], 'facility': 'Texas Oncology', 'geoPoint': {'lat': 32.35126, 'lon': -95.30106}}, {'zip': '84106', 'city': 'Salt Lake City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Emra Kazic', 'role': 'CONTACT', 'email': 'studies@utahcancer.com'}], 'facility': 'Utah Cancer Specialists', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '84112', 'city': 'Salt Lake City', 'state': 'Utah', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Devin Baxter', 'role': 'CONTACT', 'phone': '801-587-4767'}], 'facility': 'University of Utah Health Huntsman Cancer Hospital', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '24014', 'city': 'Roanoke', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Monica Sarp', 'role': 'CONTACT', 'email': 'monica.sarp@usoncology.com'}], 'facility': 'Oncology & Hematology Associates of Southwest Virginia', 'geoPoint': {'lat': 37.27097, 'lon': -79.94143}}, {'zip': '99202', 'city': 'Spokane', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Krystal Swenson', 'role': 'CONTACT', 'phone': '509-228-1682'}], 'facility': 'Cancer Care Northwest', 'geoPoint': {'lat': 47.65966, 'lon': -117.42908}}, {'city': 'Brussels', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Roxane Watterman', 'role': 'CONTACT'}], 'facility': 'Cliniques universitaires Saint-Luc', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Brussels', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Sophie Coutinho-Coelho', 'role': 'CONTACT'}], 'facility': 'Institut Jules Bordet', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Ghent', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Ellen De Bruycker, MD', 'role': 'CONTACT'}], 'facility': 'UZ Gent', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'city': 'Namur', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Dominique Crasson', 'role': 'CONTACT'}], 'facility': 'Chu Ucl Namur Site De Sainte-Elisabeth', 'geoPoint': {'lat': 50.4669, 'lon': 4.86746}}, {'city': 'Bordeaux', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Delphine Padenon', 'role': 'CONTACT'}], 'facility': 'Hopital Saint Andre, CHU Bordeaux', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'city': 'Lyon', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Martin Porret', 'role': 'CONTACT'}], 'facility': 'Centre Leon Berard', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'city': 'Marseille', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Leyla Ameur, MD', 'role': 'CONTACT'}], 'facility': 'Hopital La Timone', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Montpellier', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Justine Rochet', 'role': 'CONTACT'}], 'facility': 'Institut Régional du Cancer de Montpellier', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'city': 'Nice', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Morgane Sgorlon', 'role': 'CONTACT'}], 'facility': 'Centre Antoine Lacassagne', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Lucas Frezouls', 'role': 'CONTACT'}], 'facility': 'Institut Curie', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Thinhinane Ould Taleb', 'role': 'CONTACT'}], 'facility': 'Institut Gustave Roussy', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Rouen', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Amelie Poullain', 'role': 'CONTACT'}], 'facility': 'Centre Henri Becquerel', 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'city': 'Amsterdam', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Lotte Heimans', 'role': 'CONTACT'}], 'facility': 'NKI - Antoni van Leeuwenhoek', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'city': 'Nijmegen', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Mirte Meijerinck', 'role': 'CONTACT'}], 'facility': 'UMC Radboud', 'geoPoint': {'lat': 51.8425, 'lon': 5.85278}}, {'city': 'Utrecht', 'status': 'RECRUITING', 'country': 'Netherlands', 'contacts': [{'name': 'Sanne Bouwhuis', 'role': 'CONTACT'}], 'facility': 'UMC Utrecht', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'city': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Antonio Molina', 'role': 'CONTACT'}], 'facility': "Vall d'Hebron", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Marta Gutierrez', 'role': 'CONTACT', 'email': 'Unidadfase1.imas12@h12o.es'}], 'facility': 'Hospital 12 de Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Pamplona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Mercedes Egana', 'role': 'CONTACT'}], 'facility': 'Clinica Universidad de Navarra', 'geoPoint': {'lat': 42.81687, 'lon': -1.64323}}, {'city': 'Pamplona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Teresa Prieto', 'role': 'CONTACT'}], 'facility': 'Hospital Universitario de Navarra', 'geoPoint': {'lat': 42.81687, 'lon': -1.64323}}, {'city': 'Valencia', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Laura Bailach', 'role': 'CONTACT', 'email': 'datamanager38@fincivo.org'}], 'facility': 'Instituto Valenciano de Oncologia', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Cambridge', 'status': 'COMPLETED', 'country': 'United Kingdom', 'facility': 'Cambridge University Hospitals NHS Foundation Trust', 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Valentina Achugo', 'role': 'CONTACT'}], 'facility': 'Sarah Cannon Research Institute', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'centralContacts': [{'name': 'Gianluca Laus, MD', 'role': 'CONTACT', 'email': 'enquiries@merus.nl', 'phone': '+31 85 016 2500'}, {'name': 'Ernesto Wasserman, MD', 'role': 'CONTACT', 'email': 'USenquiries@merus.nl', 'phone': '+1 617 401 4499'}], 'overallOfficials': [{'name': 'Gianluca Laus, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Merus N.V.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Merus N.V.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}